Sign Out
Pregnancy: Pregnancy Category X. Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Atorvastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards to the fetus. If the patient becomes pregnant while taking this drug, therapy should be discontinued and the patient apprised of the potential hazard to the fetus.
Lactation: It is not known whether atorvastatin is excreted in human milk; therefore, women taking atorvastatin should not breastfeed because of the potential for adverse reactions in breastfed infants.
